Forest Labs Subpoenaed Over New COPD Inhaler

Law360, New York (May 24, 2013, 2:23 PM EDT) -- Forest Laboratories Inc. has been targeted by the U.S. Department of Justice in a New York-based probe over its recently released chronic obstructive pulmonary disease treatment Tudorza Pressair, the company revealed Thursday.

According to a report filed with the U.S. Securities and Exchange Commission, the drugmaker had received a subpoena May 6 from the U.S. Attorney’s Office in Manhattan, requesting unspecified documents relating to Tudorza Pressair, its inhaler treatment for chronic bronchospam — the constriction of airways — related to chronic obstructive pulmonary disease, or COPD. ...
To view the full article, register now.